- Home
- ECBK vs CTNM Comparison
ECBK vs CTNM Comparison
Compare ECBK & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ECBK
- CTNM
- Stock Information
- Founded
- ECBK 1919
- CTNM 2009
- Country
- ECBK United States
- CTNM United States
- Employees
- ECBK N/A
- CTNM N/A
- Industry
- ECBK Banks
- CTNM
- Sector
- ECBK Finance
- CTNM
- Exchange
- ECBK Nasdaq
- CTNM Nasdaq
- Market Cap
- ECBK 151.0M
- CTNM 122.9M
- IPO Year
- ECBK N/A
- CTNM 2024
- Fundamental
- Price
- ECBK $15.31
- CTNM $4.76
- Analyst Decision
- ECBK
- CTNM Strong Buy
- Analyst Count
- ECBK 0
- CTNM 4
- Target Price
- ECBK N/A
- CTNM $22.50
- AVG Volume (30 Days)
- ECBK 15.8K
- CTNM 119.1K
- Earning Date
- ECBK 08-08-2025
- CTNM 08-12-2025
- Dividend Yield
- ECBK N/A
- CTNM N/A
- EPS Growth
- ECBK 17.87
- CTNM N/A
- EPS
- ECBK 0.57
- CTNM N/A
- Revenue
- ECBK $26,906,000.00
- CTNM N/A
- Revenue This Year
- ECBK N/A
- CTNM N/A
- Revenue Next Year
- ECBK N/A
- CTNM N/A
- P/E Ratio
- ECBK $26.68
- CTNM N/A
- Revenue Growth
- ECBK 5.99
- CTNM N/A
- 52 Week Low
- ECBK $12.36
- CTNM $3.35
- 52 Week High
- ECBK $16.99
- CTNM $22.00
- Technical
- Relative Strength Index (RSI)
- ECBK 42.79
- CTNM N/A
- Support Level
- ECBK $15.05
- CTNM N/A
- Resistance Level
- ECBK $15.51
- CTNM N/A
- Average True Range (ATR)
- ECBK 0.42
- CTNM 0.00
- MACD
- ECBK -0.06
- CTNM 0.00
- Stochastic Oscillator
- ECBK 18.31
- CTNM 0.00
About ECBK ECB Bancorp Inc.
ECB Bancorp Inc operates as a bank holding company of Everett Co-operative Bank. The firm through its subsidiary engages in business consisting of taking deposits from the general public and investing those deposits, together with funds generated from operations, in one- to four-family residential real estate loans, commercial real estate, and multifamily real estate loans, construction and land loans and home equity lines of credit.
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.